When will there be a Kovid-19 treatment? Viruses are tricky enemies


Photographer: Paul Yong / Bloomberg

There is a global push to develop a vaccine to slow the spread of Kovid-19, and experts expect that many will be ready in 2021. Yet with one, coronovirus is likely to remain with us for years, demanding long efforts to find a cure for those who still fall ill.

In humanity’s millennium-long struggle against the virus, prevention from vaccines has been far more successful than treatment with drugs. In fact, modern medicine has come up with only one true cure for a viral infection. For many serious infections, the best approach is a cocktail of drugs that throw motion bumps in front of the infection.

It is a weak medical arsenal, which seems to be at ease with our viral enemies.

“They cannot live on their own, they are not independent, they cannot process food, take in oxygen, reproduce themselves without a master support system being parasitic inside a living cell , “Said Paula Cannon, a professor at the KK School of Medicine at the University of Southern California.

So why do viruses hurt humans so much? Outside the body, a vigorous hand wash is enough to kill many. Inside, the immune system’s long memory is enough to make most of it work.

This is when we run in one Problems with new viruses begin.

The coronovirus, SARS-CoV-2, is the latest in a procession of new infectious diseases that have surprised the world in recent years. The best hope against this is a vaccine, which can catch them before they prevent infection.

A vaccine is, essentially, a shortcut to immunity. But if we do not have immunity and get sick, then things get more complicated. Because viruses cannot survive on their own, they hijack our cells to multiply. This parasitic dependence makes them harder to treat with most conventional medicines. A virus is so interrelated with its host that it is difficult to hurt the other without hurting one. SARS-CoV-2 infects the airways and lungs – the things we need to breathe.

This leaves an inappropriate option according to Cannon. “I can kill the virus, but I have to kill you to do it.”

Read more: Drugs and vaccines under development for Kovid-19

For some vaccines, such as measles, sufficient herd immunity has been created that the virus can no longer catch and spread in populations. In the best case, as with smallpox, shots have driven the disease out of the human host population and into extinction.

Treating an active infection is another matter. There is one drug treatment for only one virus: Hepatitis C. Because of the “kill the virus, kill the host” problem, the best bet is often to slow down the virus significantly which can protect the body’s own function.

“When we can’t kill a virus, the best thing we can do is prevent it from replicating,” said Raid Dweck, chairman of the Cleveland Clinic Respiratory Institute in Ohio. “All we can do is shorten the duration of infection, not cure.” Even when the infection is over, the patient recovers more than he cures. ”

Remadesivir, The The only drug in widespread use targeting SARS-COV-2 works by messing with the ability to replicate the virus. This causes errors when the virus tries to copy itself. It was also a product of luck: the drug was originally developed as a treatment for Ebola, but was not very effective and the outbreak in Africa made it difficult to study for its manufacturer, Gilead Sciences Inc. made.

Clinical trials have shown that Remedisvir can help hospitalized Kovid-19 patients recover more quickly. But this is not a cure, and it is unlikely that there will be any time soon.

“It will take years for powerful and specific drugs that the coronovirus can stop in its tracks,” Cannon said. “The vast majority of drug candidates fail.”

In the future, patients will likely receive a cocktail of treatments attacking viruses and others that help keep them stable. Currently, Remedisvir is part of a cocoon of care that includes only other clear therapies, steroid dexamethasone, as well as fluid-like standard fare, and invasive approaches when required to include patients on ventilators. Other drugs layered topically: blood thinners and experimental approaches to calm a potentially hyperactive immune system.

As new approaches reach the market, they will be added to the mix. But for most people, an already formidable and current approach to any viral treatment would have to be improved: the human immune system.

Greatest save of all time

It is not a coincidence that many infections lasted about two weeks, Cannon said. How long does it take for the immune system to kick into gear.

“Our immune system is the best drug maker in the world,” she said. “Whether you had measles as a 5-year-old or Kovid as a 50-year-old, our immune system includes this vast library of potential antiviral approaches that provide protection.”

Cannons said that there are anti-infection proteins, biological drugs, produced to drive away foreign invaders. The body has the ability to make millions and millions, activating just the right one when it binds a virus – then producing it over a period of about 14 days.

“This is when the immune system gets the upper hand,” Cannon said. “Blood has a lot of antibodies, coating the virus. They do a good job of neutralizing the virus. Ultimately, antibodies win the day. ”

Those antibodies do not completely fall to their initial low levels. Instead, they remain on reserve and patrol for years, in case of endangerment. If this happens, the response does not take 14 days.

“If you get the same virus, the infection doesn’t go away because antibodies kick in,” Cannon said. “You don’t even get sick. Therefore, with most viruses, you acquire them once and you are immune in the future. ”

It is this process that mimics the vaccine. Man-made vaccinations provide the immune system with a piece of the virus, providing enough for the body to activate against a potential threat without making the body truly ill. The immune system is thus alert and capable of preventing infection, rather than fighting one.

There is a view behind it Another wave of therapy in development for more severe Kovid-19 patients. Drugmakers have figured out how to develop antibodies that mimic the natural substances the body produces, and experimental drugs based on them are coming from Resigneron Pharmaceuticals Inc., Roach Holding AG and Eli Lilly & Company.

But those treatments are likely to be reserved for the sickest, hospitalized patients. And those types of treatments are expensive – thousands of dollars for a course. Gilead’s hepatitis C drug, for example, cost $ 84,000, since it was approved for US sale in 2013. Biotechnology medicines under development for Kovid-19 likewise cost thousands of dollars per course. Vaccines, on the other hand, are cheaper – and keep people away from more expensive care.

“Because we can’t treat them very well, the Cleveland Clinic’s Dweck said, the important thing is always prevention.” “Once you are infected, there is very little that we can support you through or maybe make it a little shorter. That’s why finding a vaccine is so important. “

Drugmaker Incentive

There are hundreds of viruses that cause respiratory infections and are usually lumped together under the “common cold” banner. There are many coronations. The reasons we do not have treatment are because each is individual to individual and drug development is so expensive, often topping $ 1 billion per therapeutic. Each treatment must be tailored to a specific pathogen, following a tailor-made path so narrow that it would be nearly impossible. Already, thousands have failed.

And a cold? It usually goes on its own.

Comprehensive economics has historically worked against drugs for viral infections, leaving a gap in the type of innovation that has occurred, along with other profitable conditions such as cancer and heart disease. The most recent viral outbreak, which includes both SARS and MERS, both novel coronaviruses, as well as zika, led everyone to gain a foothold before new treatments.

    .

Leave a Reply